DOCSLIB.ORG

(51) International Patent Classification: A61K 8/66 (2006.01) A61Q 11/00

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(51) International Patent Classification: A61K 8/66 (2006.01) A61Q 11/00 ( (51) International Patent Classification: A61K 8/66 (2006.01) A61Q 11/00 (2006.01) (21) International Application Number: PCT/EP20 19/08 1186 (22) International Filing Date: 13 November 2019 (13. 11.2019) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 18206133.3 14 November 2018 (14. 11.2018) EP (71) Applicant: NOVOZYMES A/S [DK/DK]; Krogshoejvej 36, 2880 Bagsvaerd (DK). (72) Inventors: DURHUUS, Thomas, Thomasen; Krogshoe¬ jvej 36, 2880 Bagsvaerd (DK). PALMEN, Lorena, Gonzalez,; Krogshoejvej 36, 2880 Bagsvaerd (DK). REISER, Anna, Verena,; Krogshoejvej 36, 2880 Bagsvaerd (DK). STREICHER, Werner, W,; Krogshoe¬ jvej 36, 2880 Bagsvaerd (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available) : AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available) : ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, Cl, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (54) Title: ORAL CARE COMPOSITION COMPRISING A POLYPEPTIDE HAVING DNASE ACTIVITY (57) Abstract: The invention provides relates to oral care compositions comprising a polypeptide having DNase activity and at least one oral care component. ORAL CARE COMPOSITION COMPRISING A POLYPEPTIDE HAVING DNASE ACTIVITY REFERENCE TO SEQUENCE LISTING This application contains a Sequence Listing in computer readable form. The computer readable form is incorporated herein by reference. FIELD OF THE INVENTION The present invention relates to oral care compositions comprising a polypeptide having DNase activity and at least one oral care component. BACKGROUND OF THE INVENTION: Biofilms are communities of bacteria that are found on solid surfaces in many different environments, including surfaces of the oral cavity. Oral biofilm, or dental plague, contains many of the bacteria that are associated with oral health issues such as oral malodor, demineralization, dental caries, tooth decay, potential loss of teeth and gum disease (gingivitis and periodontitis). The formation of oral biofilm occurs in three stages known as the lag phase, growth phase, and steady state, respectively. In the lag phase, glycoproteins from saliva bind to an oral surface such as teeth and create a structure termed the pellicle that functions as attachment site for bacteria. In the growth phase, co-aggregation occurs, i.e., secondary bacterial colonizers attach to the primary bacterial colonizers, causing the diversity of the biofilm to increase and the biofilm to grow and mature. In the steady state, the biofilm growth slows down and eventually stops. This stage-based formation cycle causes biofilms to exist in several consecutive layers, which makes physical abrasion of biofilm more difficult. Within a biofilm, the residing bacterial cells are distributed in an extracellular polymeric matrix that consists primarily of water, proteins, exopolysaccharides, lipopolysaccharides, lipids, surfactants, and extracellular DNA (eDNA). eDNA is an important component of the extracellular polymeric matrix and plays a vital role in both the formation and stability of biofilm and in the antimicrobial properties of its embedded bacteria. eDNA in biofilm is known to influence the initial attachment and adhesion of biofilm to surfaces as well as the subsequent buildup, and eDNA also has a stabilizing effect on biofilms as it coats the surface of the biofilm. Moreover, eDNA derived from lysed bacteria may contain genes conferring resistance to anti-microbial agents. In case such DNA fragments are transferred within the biofilm and integrated into the chromosome of living bacterial cells, this may lead to new phenotypes with improved anti-microbial resistance profiles. Because of the increased resistance to anti-microbial agents as well as the mechanical properties of biofilm, many current oral care products are rather inefficient in addressing biofilm formation and alleviating the associated oral health issues. The main focus for biofilm removal has been on mechanical abrasion. However, this approach is difficult due to the multilayered nature of biofilms and is further compromised by the fact that mechanical removal of biofilm, e.g., by brushing the teeth, expands and deepens the areas in the oral cavity where biofilms attach and expand, thus potentially increasing the severity of the problem rather than reducing it. In view of the important role of biofilm in oral disease, there is a need in the art for oral care compositions that can effectively target oral biofilm. In particular, there is a need for oral care formulations that can target biofilm by removing the eDNA. However, this would require agents such as enzymes that at the same time are effective against biofilm as well as stable under conditions suitable for oral care, including in oral care formulations. WO 201 1/098579 relates to NucA/NucB-type deoxyribonucleases and methods for biofilm disruption and prevention. SUMMARY OF THE INVENTION In a first aspect, the present invention relates to an oral care composition comprising a polypeptide having DNase activity and at least one oral care component. In a second aspect, the present invention relates to a composition according to the first aspect for use as a medicament. In a third aspect, the present invention relates to a composition according to the first aspect for use in the treatment of oral disease. In a fourth aspect, the present invention relates to use of a composition according to the first aspect for treatment or prophylactic treatment of a human or animal subject. In a fifth aspect, the present invention relates to a method of treatment of a human or animal subject, the method comprising administering a composition according to the first aspect to a human or animal subject. In a sixth aspect, the present invention relates to a kit of parts comprising: a) a composition according to the first aspect; and b) instructions for use. BRIEF DESCRIPTION OF DRAWINGS Fig. 1 shows an example of the thermal stability data generated using the nanoDSF instrument. Panel A is an example of the data obtained (the ratio of the fluorescence emission at 350 nm to 330 nm) in triplicate for SEQ ID NO: 32 (for clarity only every fifth data point is shown) as a function of temperature. Panel B shows the first derivative of the raw data in Panel A . The peak maximum in the first derivative plot corresponds to the mid-point of the thermal unfolding transition, referred to as Td. In this example the Td corresponds to 58°C and is highly reproducible within the three replicates. Fig. 2 shows the average thermal stability of DNases in 1 mM EDTA (black bars) or 5 mM EDTA (grey bars). The dotted line represents the average for all Td values measured in EDTA. Fig. 3 shows thermal stability of DNases in the presence of 1 or 5% sodium dodecyl sulphate (SDS). The dotted line represents the average for all Td values measured in SDS. Fig. 4 shows thermal stability of DNases in the presence of 45 or 90% Plax COOL MINT (Colgate®) mouthwash. The dotted line represents the average for all Td values measured in mouthwash Plax COOL MINT (Colgate®). Fig. 5 shows thermal stability of DNases in the presence of 1 or 10% (w/v) Cavity Protection Caries toothpaste (Colgate®, Colgate-Palmolive). The dotted line represents the average for all Td values measured in Cavity Protection Caries toothpaste (Colgate ® , Colgate- Palmolive). DEFINITIONS: Clade: The term “clade” means a group of polypeptides clustered together on the basis of homologous features traced to a common ancestor. Polypeptide clades can be visualized as phylogenetic trees and a clade is a group of polypeptides that consists of a common ancestor and all its lineal descendants. Polypeptides forming a group within the clade (a subclade) of the phylogenetic tree can also share common properties and are more closely related than other polypeptides in the clade. Dentures: The term “dentures” is meant to cover dentures as such as well as braces, aligners, retainers, and the like. Polypeptide having DNase activity: The term “polypeptide having DNase activity” means a polypeptide with DNase (deoxyribonuclease) activity that catalyzes the hydrolytic cleavage of phosphodiester linkages in a DNA backbone, thus degrading DNA. Exodeoxyribonuclease cut or cleaves residues at the end of the DNA back bone where endo-deoxyribonucleases cleaves or cut within the DNA backbone. A DNase may cleave only double-stranded DNA or may cleave double stranded and single stranded DNA. The term “DNases” and the expression “a polypeptide with DNase activity” are used interchangeably throughout this application. For purposes of the present invention, DNase activity is determined according to the procedure described in the Assay I or Assay II. Nomenclature For purposes of the present invention, the nomenclature [G/N] means that the amino acid at this position may be a glycine (Gly, G) or an asparagine (Asn, N).
Load more

Recommended publications
  • Purification, Crystallization and Preliminary X-Ray Diffraction Analysis of Exodeoxyribonuclease III from Crenarchaeon Sulfolobus Tokodaii Strain 7
    Crystal Structure Theory and Applications, 2013, 2, 155-158 Published Online December 2013 (http://www.scirp.org/journal/csta) http://dx.doi.org/10.4236/csta.2013.24021 Purification, Crystallization and Preliminary X-Ray Diffraction Analysis of Exodeoxyribonuclease III from Crenarchaeon Sulfolobus tokodaii Strain 7 Shuichi Miyamoto1*, Chieko Naoe2, Masaru Tsunoda3, Kazuo T. Nakamura2 1Faculty of Pharmaceutical Sciences, Sojo University, Kumamoto, Japan 2School of Pharmacy, Showa University, Tokyo, Japan 3Faculty of Pharmacy, Iwaki Meisei University, Iwaki, Japan Email: *[email protected] Received October 13, 2013; revised November 12, 2013; accepted December 6, 2013 Copyright © 2013 Shuichi Miyamoto et al. This is an open access article distributed under the Creative Commons Attribution Li- cense, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. ABSTRACT Exodeoxyribonuclease III (EXOIII) acts as a 3’→5’ exonuclease and is homologous to purinic/apyrimidinic (AP) en- donuclease (APE), which plays an important role in the base excision repair pathway. To structurally investigate the reaction and substrate recognition mechanisms of EXOIII, a crystallographic study of EXOIII from Sulfolobus tokodaii strain 7 was carried out. The purified enzyme was crystallized by using the hanging-drop vapor-diffusion method. The crystals belonged to space group C2, with unit-cell parameters a = 154.2, b = 47.7, c = 92.4 Å, β = 125.8˚ and diffracted to 1.5 Å resolution. Keywords: Crenarchaeon; Crystallization; Exodeoxyribonuclease; Sulfolobus tokodaii; X-Ray Diffraction 1. Introduction formational change upon protein binding that permits complex formation and activation of attacking water, A variety of mechanisms exist to repair damaged DNA leading to incision, in the presence of Mg2+ [10,11].
    [Show full text]
  • The Rnase H-Like Superfamily: New Members, Comparative Structural Analysis and Evolutionary Classification Karolina A
    4160–4179 Nucleic Acids Research, 2014, Vol. 42, No. 7 Published online 23 January 2014 doi:10.1093/nar/gkt1414 The RNase H-like superfamily: new members, comparative structural analysis and evolutionary classification Karolina A. Majorek1,2,3,y, Stanislaw Dunin-Horkawicz1,y, Kamil Steczkiewicz4, Anna Muszewska4,5, Marcin Nowotny6, Krzysztof Ginalski4 and Janusz M. Bujnicki1,3,* 1Laboratory of Bioinformatics and Protein Engineering, International Institute of Molecular and Cell Biology, ul. Ks. Trojdena 4, PL-02-109 Warsaw, Poland, 2Department of Molecular Physiology and Biological Physics, University of Virginia, 1340 Jefferson Park Avenue, Charlottesville, VA USA-22908, USA, 3Bioinformatics Laboratory, Institute of Molecular Biology and Biotechnology, Adam Mickiewicz University, Umultowska 89, PL-61-614 Poznan, Poland, 4Laboratory of Bioinformatics and Systems Biology, Centre of New Technologies, University of Warsaw, Zwirki i Wigury 93, PL-02-089 Warsaw, Poland, 5Institute of Biochemistry and Biophysics PAS, Pawinskiego 5A, PL-02-106 Warsaw, Poland and 6Laboratory of Protein Structure, International Institute of Molecular and Cell Biology, ul. Ks. Trojdena 4, PL-02-109 Warsaw, Poland Received September 23, 2013; Revised December 12, 2013; Accepted December 26, 2013 ABSTRACT revealed a correlation between the orientation of Ribonuclease H-like (RNHL) superfamily, also called the C-terminal helix with the exonuclease/endo- the retroviral integrase superfamily, groups together nuclease function and the architecture of the numerous enzymes involved in nucleic acid metab- active site. Our analysis provides a comprehensive olism and implicated in many biological processes, picture of sequence-structure-function relation- including replication, homologous recombination, ships in the RNHL superfamily that may guide func- DNA repair, transposition and RNA interference.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials COMPARATIVE ANALYSIS OF THE TRANSCRIPTOME, PROTEOME AND miRNA PROFILE OF KUPFFER CELLS AND MONOCYTES Andrey Elchaninov1,3*, Anastasiya Lokhonina1,3, Maria Nikitina2, Polina Vishnyakova1,3, Andrey Makarov1, Irina Arutyunyan1, Anastasiya Poltavets1, Evgeniya Kananykhina2, Sergey Kovalchuk4, Evgeny Karpulevich5,6, Galina Bolshakova2, Gennady Sukhikh1, Timur Fatkhudinov2,3 1 Laboratory of Regenerative Medicine, National Medical Research Center for Obstetrics, Gynecology and Perinatology Named after Academician V.I. Kulakov of Ministry of Healthcare of Russian Federation, Moscow, Russia 2 Laboratory of Growth and Development, Scientific Research Institute of Human Morphology, Moscow, Russia 3 Histology Department, Medical Institute, Peoples' Friendship University of Russia, Moscow, Russia 4 Laboratory of Bioinformatic methods for Combinatorial Chemistry and Biology, Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow, Russia 5 Information Systems Department, Ivannikov Institute for System Programming of the Russian Academy of Sciences, Moscow, Russia 6 Genome Engineering Laboratory, Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region, Russia Figure S1. Flow cytometry analysis of unsorted blood sample. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S2. Flow cytometry analysis of unsorted liver stromal cells. Representative forward, side scattering and histogram are shown. The proportions of negative cells were determined in relation to the isotype controls. The percentages of positive cells are indicated. The blue curve corresponds to the isotype control. Figure S3. MiRNAs expression analysis in monocytes and Kupffer cells. Full-length of heatmaps are presented.
    [Show full text]
  • Letters to Nature
    letters to nature Received 7 July; accepted 21 September 1998. 26. Tronrud, D. E. Conjugate-direction minimization: an improved method for the re®nement of macromolecules. Acta Crystallogr. A 48, 912±916 (1992). 1. Dalbey, R. E., Lively, M. O., Bron, S. & van Dijl, J. M. The chemistry and enzymology of the type 1 27. Wolfe, P. B., Wickner, W. & Goodman, J. M. Sequence of the leader peptidase gene of Escherichia coli signal peptidases. Protein Sci. 6, 1129±1138 (1997). and the orientation of leader peptidase in the bacterial envelope. J. Biol. Chem. 258, 12073±12080 2. Kuo, D. W. et al. Escherichia coli leader peptidase: production of an active form lacking a requirement (1983). for detergent and development of peptide substrates. Arch. Biochem. Biophys. 303, 274±280 (1993). 28. Kraulis, P.G. Molscript: a program to produce both detailed and schematic plots of protein structures. 3. Tschantz, W. R. et al. Characterization of a soluble, catalytically active form of Escherichia coli leader J. Appl. Crystallogr. 24, 946±950 (1991). peptidase: requirement of detergent or phospholipid for optimal activity. Biochemistry 34, 3935±3941 29. Nicholls, A., Sharp, K. A. & Honig, B. Protein folding and association: insights from the interfacial and (1995). the thermodynamic properties of hydrocarbons. Proteins Struct. Funct. Genet. 11, 281±296 (1991). 4. Allsop, A. E. et al.inAnti-Infectives, Recent Advances in Chemistry and Structure-Activity Relationships 30. Meritt, E. A. & Bacon, D. J. Raster3D: photorealistic molecular graphics. Methods Enzymol. 277, 505± (eds Bently, P. H. & O'Hanlon, P. J.) 61±72 (R. Soc. Chem., Cambridge, 1997).
    [Show full text]
  • The Microbiota-Produced N-Formyl Peptide Fmlf Promotes Obesity-Induced Glucose
    Page 1 of 230 Diabetes Title: The microbiota-produced N-formyl peptide fMLF promotes obesity-induced glucose intolerance Joshua Wollam1, Matthew Riopel1, Yong-Jiang Xu1,2, Andrew M. F. Johnson1, Jachelle M. Ofrecio1, Wei Ying1, Dalila El Ouarrat1, Luisa S. Chan3, Andrew W. Han3, Nadir A. Mahmood3, Caitlin N. Ryan3, Yun Sok Lee1, Jeramie D. Watrous1,2, Mahendra D. Chordia4, Dongfeng Pan4, Mohit Jain1,2, Jerrold M. Olefsky1 * Affiliations: 1 Division of Endocrinology & Metabolism, Department of Medicine, University of California, San Diego, La Jolla, California, USA. 2 Department of Pharmacology, University of California, San Diego, La Jolla, California, USA. 3 Second Genome, Inc., South San Francisco, California, USA. 4 Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA, USA. * Correspondence to: 858-534-2230, [email protected] Word Count: 4749 Figures: 6 Supplemental Figures: 11 Supplemental Tables: 5 1 Diabetes Publish Ahead of Print, published online April 22, 2019 Diabetes Page 2 of 230 ABSTRACT The composition of the gastrointestinal (GI) microbiota and associated metabolites changes dramatically with diet and the development of obesity. Although many correlations have been described, specific mechanistic links between these changes and glucose homeostasis remain to be defined. Here we show that blood and intestinal levels of the microbiota-produced N-formyl peptide, formyl-methionyl-leucyl-phenylalanine (fMLF), are elevated in high fat diet (HFD)- induced obese mice. Genetic or pharmacological inhibition of the N-formyl peptide receptor Fpr1 leads to increased insulin levels and improved glucose tolerance, dependent upon glucagon- like peptide-1 (GLP-1). Obese Fpr1-knockout (Fpr1-KO) mice also display an altered microbiome, exemplifying the dynamic relationship between host metabolism and microbiota.
    [Show full text]
  • Prediction of Novel Inhibitors Against Exodeoxyribonuclease І of H
    International Journal of Scientific & Engineering Research, Volume 6, Issue 2, February-2015 217 ISSN 2229-5518 Prediction of Novel Inhibitors against Exodeoxyribonuclease І of H. influenzae through In Silico Approach Shaik Parveen, Natarajan Pradeep, Kanipakam Hema and Amineni Umamaheswari Abstract — These Haemophilus influenzae is a Gram-negative bacterium which causes pneumonia in humans. Due to its multidrug resistance to peni- cillin, rifampin and polymyxin and adverse effects of existing treatments, the condition became an open challenge for many researchers to discover novel antagonists for the treatment of pneumonia caused by H. influenzae. 5 potential sRNA candidates were identified in H. influenzae using sRNA predict tool, among them3 were enzymes and 2 were non-enzymes. Among the three identified enzymes exodeoxyribonuclease І of H. influenzae was non- homologous to humans was selected as novel drug target in the present study. Exodeoxyribonuclease І is an enzyme involved in the mismatch repair mechanism of H. influenzae. The 3D structure of the exodeoxyribonuclease І was modeled based on the crystal structure of 4JRP using Modeler 9v13 and built model was validated using PROCHECK analysis, ProQ and ProSA. The existing eight inhibitors of exodeoxyribonuclease І were searched in 3D ligand database through shape screening against ASINEX database using Phasev3.2 module and structural analogs were docked with exodeoxyri- bonuclease І in Maestro v9.6 virtual screening workflow, that implements three stage Glide docking protocol. The docking results revealed that 11 leads were having better docking and ∆G scores when compared with the eight existing inhibitors among them lead 1 was having ∆G score of -68.78 kcal/mol.
    [Show full text]
  • 12) United States Patent (10
    US007635572B2 (12) UnitedO States Patent (10) Patent No.: US 7,635,572 B2 Zhou et al. (45) Date of Patent: Dec. 22, 2009 (54) METHODS FOR CONDUCTING ASSAYS FOR 5,506,121 A 4/1996 Skerra et al. ENZYME ACTIVITY ON PROTEIN 5,510,270 A 4/1996 Fodor et al. MICROARRAYS 5,512,492 A 4/1996 Herron et al. 5,516,635 A 5/1996 Ekins et al. (75) Inventors: Fang X. Zhou, New Haven, CT (US); 5,532,128 A 7/1996 Eggers Barry Schweitzer, Cheshire, CT (US) 5,538,897 A 7/1996 Yates, III et al. s s 5,541,070 A 7/1996 Kauvar (73) Assignee: Life Technologies Corporation, .. S.E. al Carlsbad, CA (US) 5,585,069 A 12/1996 Zanzucchi et al. 5,585,639 A 12/1996 Dorsel et al. (*) Notice: Subject to any disclaimer, the term of this 5,593,838 A 1/1997 Zanzucchi et al. patent is extended or adjusted under 35 5,605,662 A 2f1997 Heller et al. U.S.C. 154(b) by 0 days. 5,620,850 A 4/1997 Bamdad et al. 5,624,711 A 4/1997 Sundberg et al. (21) Appl. No.: 10/865,431 5,627,369 A 5/1997 Vestal et al. 5,629,213 A 5/1997 Kornguth et al. (22) Filed: Jun. 9, 2004 (Continued) (65) Prior Publication Data FOREIGN PATENT DOCUMENTS US 2005/O118665 A1 Jun. 2, 2005 EP 596421 10, 1993 EP 0619321 12/1994 (51) Int. Cl. EP O664452 7, 1995 CI2O 1/50 (2006.01) EP O818467 1, 1998 (52) U.S.
    [Show full text]
  • Polyamines Mitigate Antibiotic Inhibition of A.Actinomycetemcomitans Growth
    Polyamines Mitigate Antibiotic Inhibition of A.actinomycetemcomitans Growth THESIS Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Allan Wattimena Graduate Program in Dentistry The Ohio State University 2017 Master's Examination Committee: Dr John Walters, Advisor Dr Purnima Kumar Dr Sara Palmer Dr Shareef Dabdoub Copyright by Allan Wattimena 2017 Abstract Polyamines are ubiquitous polycationic molecules that are present in all prokaryotic and eukaryotic cells. They are the breakdown products of amino acids and are important modulators of cell growth, stress and cell proliferation. Polyamines are present in higher concentrations in the periodontal pocket and may affect antibiotic resistance of bacterial biofilms. The effect of polyamines was investigated with amoxicillin (AMX), azithromycin (AZM) and doxycycline (DOX) on the growth of Aggregatibacter actinomycetemcomitans (A.a.) Y4 strain. Bacteria were grown in brain heart infusion broth under the following conditions: 1) A.a. only, 2) A.a. + antibiotic, 3) A.a. + antibiotic + polyamine mix (1.4mM putrescine, 0.4mM spermidine, 0.4mM spermine). Growth curve analysis, MIC determination and metatranscriptomic analysis were carried out. The presence of exogenous polyamines produced a small, but significant increase in growth of A.a. Polyamines mitigated the inhibitory effect of AMX, AZM and DOX on A.a. growth. Metatranscriptomic analysis revealed differing transcriptomic profiles when comparing AMX and AZM in the presence of polyamines. Polyamines produced a transient mitigation of AMX inhibition, but did not have a significant effect on gene transcription. Many gene transcription changes were seen when polyamines were in the presence of AZM.
    [Show full text]
  • WGCNA Module Annotation
    WGCNA module annotation 1. C. dipterum, D. melanogaster and S. maritima module annotations Module colour and annotated names…………………………………………………….page 2 2. C. dipterum module RNA-seq expression and GO terms………………………………..page 3 3. D. melanogaster module RNA-seq expression and GO terms………………………page 14 4. S. maritima module RNA-seq expression and GO terms……………………………...page 23 C. dipterum WGCNA modules annotation D. melanogaster WGCNA modules annotation S.maritima WGCNA modules annotation Module Colour Module annotated name Module Colour Module annotated name Module Colour Module annotated name grey60 Vesicle transport darkgrey Gut lightcyan Head greenyellow Brain darkturquoise Larval CNS saddlebrown Adult male sienna3 Cytoskeleton salmon Jump Muscle greenyellow Neurogenesis lightgreen Pre-nymph red Salivary glands red Fat body yellow Wing blue Brain- Synapsis darkgreen membrane steelblue Malpighian tube greenyellow Wing Disc skyblue Embryo/Nerve cord brown Gills cyan 12-14 hpf embryo orange Protein synthesis orange Cuticle black Flight muscle black Nerve cord- Synapsis blue Muscle magenta 4-6 h embryo- Transcription midnightblue Splicing skyblue Chitin purple Adult heads- visual perception blue Gut yellowgreen Trachea green Ovaries grey60 Malpighian tubes black Gut lightcyan Fat body purple Fat body B- Translation paleturquoise Gut/Malpighian white Muscle- Cell metabolism white Proteasome cyan Protein synthesis brown Testis lightgreen Cellular respiration tan 10 dpf embryo- Neurogenesis pink Malpighian tubule magenta Ovaries-Replication darkolivegreen Brain B- Lipid metabolism skyblue Adult gut lightyellow Fatty acid metabolism magenta Male Head- Phototransduction grey60 Larval gut royalblue Cellular metabolism turquoise Ovaries darkorange Fat body- Post-translation modification darkmagenta Female Head- Fatty acid metabolism brown Embryogenesis red 4 dpf embryo- Autophagy turquoise Testis-Cilium saddlebrown Embryogenesis- Synapsis darkgrey Transcription green Testis C.
    [Show full text]
  • Bacterial Retrons Encode Tripartite Toxin/Antitoxin Systems
    bioRxiv preprint doi: https://doi.org/10.1101/2020.06.22.160168; this version posted June 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. 1 Bacterial retrons encode tripartite toxin/antitoxin systems 2 3 Jacob Bobonis1,2, André Mateus1, Birgit Pfalz1, Sarela Garcia-Santamarina1, Marco Galardini3, 4 Callie Kobayashi4, Frank Stein5, Mikhail M. Savitski1,5,6, Johanna R. Elfenbein7,8*, Helene 5 Andrews-Polymenis4* and Athanasios Typas1,6* 6 7 * Correspondence: [email protected], [email protected] & [email protected] 8 9 1 European Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany 10 2 Collaboration for joint PhD degree between EMBL and Heidelberg University, Faculty of Biosciences 11 3 European Molecular Biology Laboratory, European Bioinformatics Institute, Hinxton, UK 12 4 Texas A&M University, Department of Microbial Pathogenesis and Immunology, Texas, USA 13 5 European Molecular Biology Laboratory, Proteomics Core Facility, Heidelberg, Germany 14 6 European Molecular Biology Laboratory, Structural and Computational Biology Unit, Heidelberg, 15 Germany 16 7 University of Wisconsin-Madison, Department of Pathobiological Sciences, Madison, WI, USA 17 8 North Carolina State University, Department of Clinical Sciences, Raleigh, NC, USA 18 19 ABSTRACT 20 Retrons are genetic retroelements, commonly found in bacterial genomes and recently 21 repurposed as genome editing tools. Their encoded reverse transcriptase (RT) produces a 22 multi-copy single-stranded DNA (msDNA). Despite our understanding of their complex 23 biosynthesis, the function of msDNAs and therefore, the physiological role of retrons has 24 remained elusive.
    [Show full text]
  • Enzyme-Pore Constructs
    (19) TZZ Z_T (11) EP 2 682 460 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 08.01.2014 Bulletin 2014/02 C12N 9/12 (2006.01) C12N 9/22 (2006.01) C12N 9/52 (2006.01) C12Q 1/68 (2006.01) (21) Application number: 13187149.3 (22) Date of filing: 06.07.2009 (84) Designated Contracting States: • Cheley, Stephen AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Oxford HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL Oxfordshire OX4 4GA (GB) PT RO SE SI SK SM TR •McKeown,Brian Oxford (30) Priority: 07.07.2008 US 78695 P Oxfordshire OX4 4GA (GB) • White, James (62) Document number(s) of the earlier application(s) in Oxford accordance with Art. 76 EPC: Oxfordshire OX4 4GA (GB) 09784644.8 / 2 307 540 • Clarke, James Oxford (71) Applicant: Oxford Nanopore Technologies Oxfordshire OX4 4GA (GB) Limited Oxford Science Park (74) Representative: Chapman, Lee Phillip Oxford J A Kemp OX4 4GA (GB) 14 South Square Gray’s Inn (72) Inventors: London WC1R 5JJ (GB) • Jayasinghe, Lakmal Oxford Remarks: Oxfordshire OX4 4GA (GB) This application was filed on 02-10-2013 as a •Bayley,Hagan divisional application to the application mentioned Oxford under INID code 62. Oxfordshire OX4 4GA (GB) (54) Enzyme-pore constructs (57) The invention relates to constructs comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme. The pore subunit is covalently at- tached to the enzyme such that both the subunit and enzyme retain their activity.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]